Talis Biomedical Corporation (TLIS)
NASDAQ: TLIS · IEX Real-Time Price · USD
9.00
+0.10 (1.12%)
Apr 22, 2024, 4:00 PM EDT - Market closed
Company Description
Talis Biomedical Corporation operates as a molecular diagnostic company.
The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases.
It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B.
The company was incorporated in 2013 and is headquartered in Redwood, California.
Talis Biomedical Corporation
| Country | United States |
| Founded | 2010 |
| IPO Date | Feb 12, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 99 |
| CEO | Robert Kelley MBA |
Contact Details
Address: 1100 Island Drive, Suite 101 Redwood City, California 94065 United States | |
| Phone | 650-433-3000 |
| Website | talisbio.com |
Stock Details
| Ticker Symbol | TLIS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001584751 |
| CUSIP Number | 87424L108 |
| ISIN Number | US87424L2079 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Robert Kelley MBA | Chief Executive Officer and Director |
| Dr. Andrew A. Lukowiak Ph.D. | President and Chief Scientific Officer |
| Dr. Rustem F. Ismagilov Ph.D. | Co-Founder and Director |
| Rebecca Markovich | Interim Chief Financial Officer |
| Liang Li Ph.D. | Co-Founder and Director of Technology and Strategy |
| Emily Faucette | Senior Vice President of Corporate Communications and Investor Relations |
| Jill Green | Senior Vice President of Legal |
| Matthew Pepe | Vice President of Human Resource |
| Margaret Barrett M.S. | Controller |
| Gillian Green | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | 8-K | Current Report |
| Mar 29, 2024 | EFFECT | Notice of Effectiveness |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | POS AM | Post-Effective amendments for registration statement |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2024 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |
| Nov 14, 2023 | 8-K | Current Report |
| Sep 1, 2023 | 8-K | Current Report |
| Aug 10, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |